Abstract
Hyperhomocysteinemia is associated with arterial hypertension and endothelial dysfunction in healthy humans. Placebo-controlled vitamin intervention studies cannot distinguish intrinsic actions of homocysteine (tHcy) and folate concentrations on the endothelium. The present two-period crossover study investigates the effects of tHcy lowering through oral folic acid on antioxidant status and resistance vessel reactivity in patients with established coronary artery disease (CAD). We investigated 27 male patients with angiographically documented multivessel CAD aged 50 (range 46–56) years. Resistance vessel reactivity was assessed by measurement of postischemic reactive hyperemia (RH) in the forearm using venous occlusion plethysmography at baseline, after 6 weeks of treatment with 5 mg of oral folic acid, and after a washout period of another 6 weeks. Plasma folate increased 3.49-fold with a mean tHcy reduction of 21.3%. Peak reactivity of resistance vessels improved significantly (18.97–23.60 ml/min−1 per 100 ml; P = 0.01) with unchanged total antioxidant status (TAS; 0.912–0.944 μM;P = 0.4). This effect was limited to subjects (n = 14) with a tHcy reduction >2 μM (median reduction, 14.4–9.6 μM, P < 0.001). In the 13 subjects with a below-median reduction, tHcy remained unaltered (9.7–9.6 μM, P = 0.88) and TAS increased significantly (0.923–1.055 μM, P = 0.006), whereas RH peak flow was not affected (20.22–22.99 ml/min−1 per 100 ml, P = 0.28). Homocysteine lowering >2 μM through folic acid supplementation improves resistance vessel reactivity in patients with CAD. Our data support the hypothesis that homocysteine lowering may have intrinsic vasoprotective effects largely independent of folate.
Footnotes
-
The work was primarily performed at the Departments of Surgery, Division of Cardiac Surgery and the Department of Internal Medicine, Diabetic Angiopathy Research Group, both part of the Clinical Atherosclerosis Research Group, Karl-Franzens University School of Medicine, Graz, Austria.
-
DOI: 10.1124/jpet.102.036715
- Abbreviations:
- tHcy
- total plasma homocysteine
- CAD
- coronary artery disease
- FMD
- flow-mediated dilation
- RH
- reactive hyperemia
- TAS
- total antioxidant status
- NO
- nitric oxide
- Received April 9, 2002.
- Accepted May 13, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|